When looking at valuations, Bristol-Myers Squibb Company (BMY) has a cheap P/E of 16.38x as compared to industry average of 32.17x. It trades for 11.17 times the next 12 months of expected earnings. It is trading at rather expensive levels at just over 5.99x price/book and 3.62x price/sales. Compared to others, Bristol-Myers Squibb Company is in a different league with regards to profitability, having net margins of 1.7%. To put some perspective around this, the industry’s average net margin is 5.98%. BMY’s ROE is 3%, which is considerably worse than the industry’s ROE of 14.33%. It’s very liquid in the near term, with a current ratio of 1.5. The stock has a debt/capital of 0.54.
Bristol-Myers Squibb Company (NYSE:BMY) is now worth $81.76B thanks to -0.24% drop in recent trade and currently has a price tag of $50.1. The shares traded as low as $49.58 and had $50.32 an intraday high earlier Monday. Trading activity significantly weakened as the volume at ready counter decreased to 13,869,983 shares versus 16,097,045 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 19,950,318 shares. The stock is now 13.09% above against its bear-market low of $44.3 on January 03, 2019. It has retreated -39.82% since it’s 52-week high of $70.05 reached in February. Now the market price is down -20.08% on the year and down -3.62% YTD.
BMY’s 50 day simple moving average (SMA 50) price is $50.26 and its 200-day simple moving average (SMA 200) price is $54.65. The company’s stock currently has a total float of 1.63B shares. Its weekly volatility is hovering around 1.85% and felt 2.31% volatility in price over a month. On the upside, the share price will test short term resistance at around $50.42. On a downside, the stock is likely to find some support, which begins at $49.68. The failure to get near-term support could push it to $49.26.
Separately, it has been reported that multiple insider activity took place at Bristol-Myers Squibb Company (BMY). Director Paliwal Dinesh C acquired 4,770 shares for $8,027 in transaction occurred on 2018/04/30. After making this transaction, the Director owns a direct stake of 249,948 shares, worth $402,153, as per the last closing price. On 2017/12/15 Samuels Theodore R. Ii, Director at BMY, purchased 4,000 shares at an average price of $62.3 per share. The new stake is valued at $1,102,200.
EVP & Chief Scientific Officer, Lynch Thomas J. Jr. had divested 5,300 shares for $9,251 through a trade on 2017/12/12. Following this activity, the insider holds 335,172 shares worth $463,475 as of recent close. Wall Street’s most bullish Bristol-Myers Squibb Company (NYSE:BMY) analysts are predicting the share price to blow past $62 per share during the next 12 months. The current median share price forecast by them is $54, suggesting that the stock could increase 7.78% in that time frame. The average price target of $56.22 calls for a nearly 12.22% increase in the stock price.
It had seen a positive analyst call from Societe Generale, which upgraded the stock from Sell to Buy on January 15. Analysts at Citigroup, shed their positive views on October 22 by lowering it fromBuy to Neutral. Analysts at Guggenheim, made their first call about the stock on October 09, recommending it is Neutral. Atlantic Equities analysts came out with bullish views on August 08 when the call was made. They think the stock is now Neutral compared to to their prior call for Underweight.
Shares of Bristol-Myers Squibb Company (BMY) have gained 0.5% since the company’s last earnings report. Over the past 12 fiscal quarters, Bristol-Myers Squibb Company (NYSE:BMY) has topped consensus earnings estimates in 10 quarters (83%), missed earnings in 2 quarters (16%), whereas at 0 occasion EPS met analyst expectations. BMY last reported earnings on January 24, 2019 when it released Dec-18 results that exceeded expectations. The company raked in $0.94 per share, -91.06% change on the same period last year. That was better than consensus for $0.85. Revenue for the recent quarter stood at $5.97 billion, up 10% on last year and below the $5.99 billion predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $5.61 billion to $6 billion, which should be compared with $5.69 billion generated last year. EPS is seen in a range of $1.01 to $1.18, against the $1.01 reported a year ago.